Pearce IP BioBlast™: w/e 01 May 2020

by , | May 4, 2020

Significant biosimilar activities this week include

23 April 2020 | Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02.

28 April 2020 | Mylan and Biocon launched Fulphila® (pegfilgrastim) in Canada. Fulphila® is approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

29 April 2020 | Gedeon Richter announced it has entered an asset purchase agreement with Mycenax Biotech for the purchase of a biosimilar tocilizumab product. Under the agreement, Richter will receive worldwide rights to develop, manufacture and commercialise the product which is expected to reach global markets in 2025.

30 April 2020 | Amgen filed suit against Hospira and Pfizer in the District Court of Delaware, alleging infringement of US patent 10,577,392, relating to the manufacture of Neupogen® (filgrastim). Interestingly, the patent was only granted on March 03, 2020, nearly 2 years after Hospira launched Nivestym®.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News